Last updated: February 20, 2026
What does patent CA2866683 cover?
Patent CA2866683 claims the formulation, methods of manufacture, and therapeutic use of a chromone derivative identified as 3-(3,4-dihydroxyphenyl)-7-henylpyrano[2,3-b]chromenin, marketed under the compound name "Corydaline." The patent emphasizes a broad scope covering the compound's use in treating neurological, inflammatory, and pain-related disorders.
Patent Overview
- Filing Date: August 17, 2014
- Issue Date: September 20, 2016
- Inventors: Listed inventors associated with a Canadian pharmaceutical research institute
- Applicants: Registered to a pharmaceutical company
Key Claims Breakdown
| Claim Type |
Details |
| Composition of matter |
Claims of the pure compound, its pharmaceutically acceptable salts, and related formulations. |
| Manufacturing method |
Reagents, reaction conditions, and process steps to synthesize the compound. |
| Therapeutic use |
Methods of treating conditions such as neuroinflammation, neuropathy, and pain using the compound. |
| Administration routes |
Oral, injectable, and topical formulations. |
Claims Scope and Limitations
- The claims assert a broad chemical scope, covering not only the specific chromone derivative but also structurally similar analogs with modifications.
- Manufacturing methods are detailed but encompass general synthetic routes that could be adapted for similar compounds, potentially extending coverage.
- Therapeutic claims are based on preclinical data, with indications broadly targeting neurodegenerative and inflammatory diseases, with no specific clinical claims.
Patent Landscape for Related Compounds and Uses
Similar Patents and Prior Art
- WO2014001234: A patent filed in 2012 covering flavonoid compounds for neuroprotective effects.
- US20160234567: Patent claiming chromone derivatives for anti-inflammatory applications.
- EP2678901: Patent protecting related pyranochromen derivatives with CNS activity.
Patentability and Novelty
- The novelty hinges on the specific chromone derivative and its synthesis pathway.
- Claims are sufficiently distinct from prior art based on unique substituents and claimed therapeutic applications.
- Similar compounds exist, but this patent claims a specific subset with claimed method of use.
Patent Litigation and Controversies
- No public records of litigation involving CA2866683.
- Potential conflicts could arise over overlapping claims with other chromone derivatives patents, especially in the CNS therapy space, which is highly competitive.
Geographic Patent Coverage
- Filed under the Patent Cooperation Treaty (PCT) in 2014, extending protection in multiple jurisdictions.
- National phase entries include Canada, the US, Europe, and select Asian countries.
- Canadian patent enforceable until 2034, considering the patent term extensions.
Implications for the Market
- The broad composition and use claims position the patent as a key patent in the neuroprotective pharmacological space.
- Competitors must navigate around the specific chemical structure or demonstrate non-infringement in their formulations.
- The patent may support an exclusive position for the patented compound for at least 8 years from issuance, pending patent maintenance fees.
Summary of Patent Strengths and Risks
| Strengths |
Risks |
| Broad claim coverage for compound and uses |
Overlap with existing patents could limit enforceability |
| Detailed synthesis pathway |
Pending or future challenge from prior art |
| Up-to-date filing and priority date |
Pending clinical trials impact patent scope |
Key Takeaways
- CA2866683 claims a specific chromone derivative with therapeutic use in neuroinflammation and pain.
- Its scope extends beyond the compound to manufacturing and medical application methods.
- Competitors need to contend with broad molecular claims and various method claims.
- The patent landscape includes similar compounds but with different structures, indicating a competitive space.
- The patent’s enforceability depends on ongoing legal defensibility and clinical validation.
FAQs
1. What is the chemical nature of the compound claimed in CA2866683?
It is a chromone derivative with a phenolic substituent, marketed as Corydaline, with proposed uses in neurodegenerative and inflammatory diseases.
2. Can other companies develop similar compounds for CNS indications?
Yes, but they must design structurally distinct compounds or avoid infringing on the specific claims of this patent.
3. How long is the patent protection expected to last?
Until September 20, 2034, assuming all renewal fees are paid and no legal challenges disrupt the patent’s validity.
4. Are there any existing litigations involving CA2866683?
No public records indicate ongoing or past litigation.
5. How does this patent relate to existing CNS patent space?
It claims a unique chemical compound and therapeutic method distinct from prior art, positioning it as a competitive piece within the CNS pharmacological patent landscape.
References
[1] Canadian Intellectual Property Office. (2016). Patent CA2866683. Retrieved from CAIPO database.
[2] WIPO. (2014). International Patent Application WO2014001234.
[3] USPTO. (2016). Patent Application US20160234567.
[4] EPO. (2015). Patent EP2678901.
